Antabio SAS raises €25 m in Series B financing

<a title="http://www.b3cnewswire.com/PRT/link.php?click=1619-2-24039-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1619-2-24039-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Antibiotics specialist Antabio SAS</a> has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from […]

Production process for cell-based coffee published

Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.

Germany blocking deregulation of NGT breeds

At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the <link https://data.consilium.europa.eu/doc/document/ST-16443-2023-INIT/en/pdf>adapted version of the EU Commission’s draft regulation</link> on new genomic […]

Germany blocks deregulation of NGT breeds

At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the <link https://data.consilium.europa.eu/doc/document/ST-16443-2023-INIT/en/pdf>adapted version of the EU Commission’s draft regulation</link> on new genomic […]

Cathera SA closes Series B round at €42m

Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.<br /> &nbsp;<br />

UK publishes £2bn vision for engineering biology

On the occasion of SynbiTECH in London, British&nbsp;Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.

Valnevas Lyme vaccine trial complets recruitment

Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.

Unveiling prostate cancer's Achilles' heel

Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.

$30m for genetic medicine advancements

Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.

Takeover in ADC space: Abbvie snags ImmunoGen

AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.